印度症状性静脉曲张患者非热非肿胀腔内胶粘消融术的疗效
该单中心回顾性观察研究纳入175例症状性静脉曲张患者共176条肢体,随访6、12、18个月,评估非热非肿胀氰基丙烯酸酯胶粘消融的闭塞率与VCSS改善。技术成功率100%,6个月静脉闭合率100%,12和18个月99.4%;VCSS从术前5.8±2.2显著降至6个月2.1±1.2(p<0.001)并持续改善。最常见副作用为血栓性静脉炎7.4%,无严重不良事件。
要点
- 技术成功率100%,6个月闭合率100%,12和18个月99.4%。
- VCSS从5.8±2.2降至6个月2.1±1.2,并持续至18个月1.4±0.67(p<0.001)。
- 血栓性静脉炎发生率7.4%,无严重不良事件及感觉异常。
核心结论
- 非热非肿胀腔内胶粘消融在印度症状性慢性静脉功能不全患者中显示高疗效与安全性。
研究设计与样本
- 单中心回顾性观察研究,纳入175例患者共176条肢体,随访6、12、18个月。
主要发现
- 技术成功率100%,无器械相关并发症。
- 静脉闭合率6个月100%,12和18个月99.4%。
- 术前VCSS 5.8±2.2,6个月降至2.1±1.2(p<0.001),12个月1.7±0.99(p<0.001),18个月1.4±0.67(p<0.001)。
- 最常见副作用为血栓性静脉炎,13/176条肢体(7.4%)。
- 无严重不良事件,未观察到感觉异常。
关键数值与推荐
- CEAP分类以C2最常见,83/176条肢体(47.2%)。
- 消融大隐静脉170条、小隐静脉5条、副大隐静脉1条。
- 术前大隐静脉直径(仰卧位)5.7±1.8 mm,消融静脉长度32.9±7 cm。
临床怎么用
- 对于症状性静脉曲张伴主干反流患者,可考虑非热非肿胀胶粘消融作为热消融的替代选择。
- 术后需关注血栓性静脉炎和过敏反应等氰基丙烯酸酯相关并发症。
局限性
- 单中心回顾性设计可能引入选择偏倚。
- 随访时间最长为18个月,缺乏更长期疗效数据。
- 样本仅来自印度人群,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Varicose vein disease is characterized by dilated and tortuous lower extremity veins and affects approximately 37.25% of Indian population. Endovenous ablation is the first-line treatment approved for superficial venous reflux. A new technology recently available is a nontumescent and nonthermal method (VenaSeal) wherein aliquots of cyanoacrylate glue are delivered throughout the length of vein resulting in venous obliteration. The aim of this study was to evaluate the clinical outcomes of endovenous glue ablation for treatment of superficial venous reflux in patients with symptomatic varicose vein disease. MATERIALS AND METHODS: This was a single-center retrospective observational study of 175 patients with 6, 12, and 18 months follow-up. The treatment success was measured in terms of vein occlusion rate on Duplex scan and clinical outcomes in terms of improvement in revised Venous Clinical Severity Score (VCSS). RESULTS: A total of 176 limbs were treated over a study period of 1 year 5 months with 6-, 12-, and 18-month follow-up. The most common CEAP classification was C2 seen in 83/176 (47.2%) limbs. Incompetent great saphenous vein (GSV) was ablated in 170, incompetent short saphenous vein (SSV) in 5 and accessory GSV in 1 patient. The preprocedure GSV diameter (supine position) was 5.7±1.8 mm and the length of ablated vein was 32.9±7 cm. The technical success was 100% with no device related complications. The vein closure rate was 100% at 6 months and 99.4% at 12 and 18 months. The preprocedural VCSS score was 5.8±2.2. There was statistically significant improvement in VCSS score at 6 months (2.1±1.2; p<0.001) with sustained improvement at 12 months (1.7±0.99; p<0.001) and 18 months (1.4±0.67; p<0.001). The most common side effect was thrombophlebitis seen in 13/176 (7.4%) limbs. There was no serious adverse event and paraesthesia was not seen. CONCLUSION: This study has demonstrated high efficacy and safety of endovenous glue ablation in terms of truncal closure, technical and clinical success in symptomatic patients with chronic venous insufficiency in Indian population. However, complications like thrombophlebitis and hypersensitivity reactions are reported with cyanoacrylate ablation.Clinical ImpactIt will authenticate the safety and efficacy of glue based ablation for the treatment of lower limb varicose veins. Cyanoacrolate glue based non thermal Ablation of lower limb Varicose Veins has better efficacy, fewer side effects and practically painless compared to thermal Ablation.
引用
- Verma M, Surya M, Yadav S, et al. Outcomes of Nonthermal and Nontumescent Endovenous Glue Ablation for Treatment of Incompetent Truncal Veins in Symptomatic Varicose Vein Disease in Indian Population. J Endovasc Ther. 2026. PMID: 41725224. doi:10.1177/15266028261417923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。